Skip to main contentSkip to main content
Updating results


Disabled patients face discrimination from doctors. More than three decades after the passage of the Americans with Disabilities Act (ADA), some doctors still harbor biases toward people with disabilities, and even actively avoid accepting them as patients, a new study finds. Read more

MONDAY, Sept. 26, 2022 (HealthDay News) -- Triplet therapy of cabozantinib + nivolumab + ipilimumab significantly improves progression-free survival (PFS) compared with placebo + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk, according to a study presented at the annual meeting of the European Society for Medical Oncology, held from Sept. 9 to 13 in Paris.

  • Updated

WEDNESDAY, Sept. 21, 2022 (HealthDay News) -- Considerable progress has been made to improve, extend, and save lives of patients with cancer in the last year, according to the 12th annual Cancer Progress Report released by the American Association for Cancer Research (AACR).

  • Updated

MONDAY, Sept. 19, 2022 (HealthDay News) -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published in the September-October issue of Practical Radiation Oncology, recommendations are presented for the use of radiation therapy (RT) in patients with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma.

THURSDAY, Sept. 15, 2022 (HealthDay News) -- Among patients with local regionally advanced oral cavity squamous cell carcinoma, rates of postoperative adverse events appear to be similar for those receiving neoadjuvant pembrolizumab or standard-of-care treatment, according to a study published online Aug. 25 in JAMA Otolaryngology-Head & Neck Surgery.

  • Updated

THURSDAY, Sept. 15, 2022 (HealthDay News) -- For patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC), preoperative fluorodeoxyglucose positron emission tomography (FDG-PET) may predict pathologic response to neoadjuvant therapy (NAT), according to a study published online Sept. 8 in the Journal of the National Comprehensive Cancer Network.

Get up-to-the-minute news sent straight to your device.


News Alerts

Breaking News